Erlotinib in wild type epidermal growth factor receptor non-small cell lung cancer: A systematic review

Background: Targeting epidermal growth factor receptors (EGFR) is an innovative approach to managing non-small cell lung cancer (NSCLC) which harbors EGFR mutation. However, the efficacy of these agents like erlotinib in patients without the mutation is not known. Methods: This systematic review in...

Cijeli opis

Bibliografski detalji

Glavni autori:	Abdul-Rahman Jazieh, Reem Al Sudairy, Nada Abu-Shraie, Wafaa Al Suwairi, Mazen Ferwana, M Hassan Murad
Format:	Artigo
Jezik:	Inglês
Izdano:	Wolters Kluwer Medknow Publications 2013-01-01
Serija:	Annals of Thoracic Medicine
Teme:	Epidermal growth factor erlotinib non-small cell lung cancer
Online pristup:	http://www.thoracicmedicine.org/article.asp?issn=1817-1737;year=2013;volume=8;issue=4;spage=204;epage=208;aulast=Jazieh
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!